Abiopharma

🔍 Patsalos-Fox Michael (Director)

Company: COGNIZANT TECHNOLOGY SOLUTIONS CORP (CTSH)

Report Date: 2026-08-25

Detailed Transactions and Holdings:

• Acquired 31 shares of Deferred Restricted Stock Units (Derivative)
  Date: 2026-08-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 5,877.99 | transaction_form_type: 4 | Footnotes: F1, F1, F2, F2
• Acquired 22 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 4,192.83 | transaction_form_type: 4 | Footnotes: F3, F3, F4, F4

Footnotes:

• F1: Reflects deferred restricted stock units received pursuant to dividend equivalent rights accrued on previously outstanding deferred restricted stock units. Each deferred restricted stock unit represents a right to receive one share of Class A Common Stock of the Company.
• F2: The deferred restricted stock units are fully vested and will be settled upon the Reporting Person's termination of service from the Board.
• F3: Reflects restricted stock units received pursuant to dividend equivalent rights accrued on previously outstanding restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Company's Class A Common Stock.
• F4: The restricted stock units will vest fully on June 2, 2027.